Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

Similar articles for PubMed (Select 23288644)

1.

Impact of genetic targets on primary brain tumor therapy: what's ready for prime time?

Zalatimo O, Zoccoli CM, Patel A, Weston CL, Glantz M.

Adv Exp Med Biol. 2013;779:267-89. doi: 10.1007/978-1-4614-6176-0_12. Review.

PMID:
23288644
2.

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.

3.

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.

4.

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.

PMID:
22287028
5.

Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.

Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T.

Neuro Oncol. 2012 Jan;14(1):109-16. doi: 10.1093/neuonc/nor185. Epub 2011 Oct 27.

6.

Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.

Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P.

Mod Pathol. 2013 Jul;26(7):922-9. doi: 10.1038/modpathol.2012.166. Epub 2013 Feb 22.

7.

IDH1 mutation of gliomas with long-term survival analysis.

Myung JK, Cho HJ, Park CK, Kim SK, Phi JH, Park SH.

Oncol Rep. 2012 Nov;28(5):1639-44. doi: 10.3892/or.2012.1994. Epub 2012 Aug 24.

PMID:
22922798
8.

Molecular profile of oligodendrogliomas in young patients.

Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, Shukla S, Somasundaram K, Mahapatra AK, Kale SS, Sarkar C.

Neuro Oncol. 2011 Oct;13(10):1099-106. doi: 10.1093/neuonc/nor146.

9.

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M.

J Clin Oncol. 2009 Dec 1;27(34):5743-50. doi: 10.1200/JCO.2009.23.0805. Epub 2009 Oct 5.

10.

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.

Neurology. 2010 Oct 26;75(17):1560-6. doi: 10.1212/WNL.0b013e3181f96282.

PMID:
20975057
11.

Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.

Xiong J, Liu Y, Wang Y, Ke RH, Mao Y, Ye ZR.

Chin Med J (Engl). 2010 Dec;123(24):3566-73.

PMID:
22166632
12.

Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1349-55. doi: 10.3174/ajnr.A2950. Epub 2012 Feb 9.

13.

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G.

Neuro Oncol. 2012 Sep;14 Suppl 4:iv100-8. doi: 10.1093/neuonc/nos206. Review.

14.

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.

Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.

Neurology. 2013 Oct 22;81(17):1515-22. doi: 10.1212/WNL.0b013e3182a95680. Epub 2013 Sep 25.

PMID:
24068788
15.

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D.

J Neurooncol. 2011 Nov;105(2):345-57. doi: 10.1007/s11060-011-0596-3. Epub 2011 Jun 4.

PMID:
21643842
16.

MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations.

Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, B├Ącklund LM, Collins VP, Ichimura K.

Int J Cancer. 2012 Sep 1;131(5):1104-13. doi: 10.1002/ijc.26499. Epub 2012 Jan 11.

PMID:
22020830
17.

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.

Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schackert G, Krex D.

J Neurooncol. 2012 Dec;110(3):325-33. doi: 10.1007/s11060-012-0977-2. Epub 2012 Sep 27. Erratum in: J Neurooncol. 2013 Jan;111(1):95. Schrok, E [corrected to Schrock, E].

PMID:
23015095
18.

Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.

Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J.

Neurol Med Chir (Tokyo). 2007 Aug;47(8):341-9; discussion 350.

19.

Glioma biology and molecular markers.

Cohen AL, Colman H.

Cancer Treat Res. 2015;163:15-30. doi: 10.1007/978-3-319-12048-5_2. Review.

PMID:
25468223
20.

[Genetic alterations and biomarkers for glioma].

Nagane M.

Brain Nerve. 2012 May;64(5):537-48. Review. Japanese.

PMID:
22570067
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk